Cibus Corp. (NASDAQ: CBUS) was founded in 2001. It is currently a British Virgin Islands company operating under the name of Cibus Global, Ltd.. After this issuance, the company will comply with Article 388 of DGCL and Article 184 of BCA. The company’s legal naturalization method will be classified as a Delaware company and will be renamed Cibus Corp., headquartered in San Diego, California, with 134 full-time employees (12/31/2018). It is an agricultural biotechnology company that uses Advanced technology develops ideal plant traits for the global seed industry.
Cibus Corp. (CBUS):
Cibus has developed and is commercializing a proprietary and highly differentiated gene editing technology, which the company calls Rapid Trait Development System (RTDS). RTDS enables companies to effectively introduce customizable, specific and predictable value-added characteristics into plants and microorganisms. This ability to precisely edit plant genes without the need to integrate exogenous genetic material or recombinant DNA makes Cibus’s technology a truly non-GMO technology in its processes and products , and differentiates the company from its competitors.
Cibus’ gene editing method accelerates the foundation of natural breeding, provides a versatile and low-cost method that can increase farmers’ crop yields, develop healthier foods for consumers, and reduce the waste of sustainable agricultural ecosystems.
Cibus Corporation believes that RTDS can transform the global seed industry by applying advanced trait development to a wider range of crops and geographic regions that are more targeted than before, enabling the company to meet the needs of the entire agricultural value chain-seeking weeds from farmers Control and disease tolerance options to obtain higher crop yields, to processors seeking to improve handleability and reduce waste, and then to consumers demanding healthier, more nutritious, and safer (for example, non-allergenic) foods .
Historically, large agrochemical companies ( Monsanto , Bayer , Syngenta, etc.) introduced ideal traits by using genetic modification methods, in which exogenous genetic material was integrated into the genetic code of plants. The integration of this recombinant DNA usually results in seeds being classified as genetically engineered, or bioengineered (“BE”) or genetically modified organisms (“GMO”), and therefore subject to strict control in many countries. The use of genetically modified technology may take more than ten years, and it is estimated that it will cost US$135 million to develop a single plant trait, evaluate its safety and obtain regulatory approval before commercialization.
In contrast, RTDS can be used to develop ideal plant traits, such as disease tolerance, and introduce them into a variety of crops within a few months, making the traits commercialized within five years and the cost is significantly lower than transgenic technology. Cibus Corporation’s target market is the $39 billion seed industry worldwide. Since the characteristic seeds developed through RTDS are non-GMO and are not subject to genetic modification regulations in some major agricultural markets, the company is able to develop characteristics that can compete in the seed market-in the $17 billion traditional seed market China (non-GMO), and a $21 billion biotech seed market (including characteristic seeds developed through biotechnology).
Cibus Corp believes that the company’s technology, business relationships and reputation in the global seed industry enable it to accelerate the growth of the already rapidly growing biotech seed market by offering competitive non-GMO options and sharing the growth of non-GMO organisms-through Non-GMO introduces ideal traits. For example, by developing disease-resistant properties to prevent key diseases, while reducing the number and frequency of pesticide applications, the company believes it can extract additional value from the global pesticide market, worth more than $15 billion, to protect crops against fungi Plant diseases.
Cibus Corp. (CBUS) investment:
Cibus Corp. (NASDAQ: CBUS) submitted its IPO prospectus on 12/21/2018, and plans to log on to Nasdaq on 2/14/2019. The issue price is $14.00-$16.00, and 6,666,667 shares will be issued. The fundraising will not exceed $122,666,672.00. , Morgan Stanley/ BofA Merrill Lynch/ Piper Jaffray underwriting.